Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations☆
Under an Elsevier user license
open archive
Keywords
Chronic obstructive pulmonary disease (COPD)
Salmeterol
Fluticasone propionate
Long-acting beta2-agonist
Inhaled corticosteroid
Exacerbations
Abbreviations
COPD
chronic obstructive pulmonary disease
FEV1
forced expiratory volume in one second
FSC
fluticasone propionate/salmeterol combination
FVC
forced vital capacity
Cited by (0)
- ☆
ClinicalTrials.gov identifier # NCT00144911.
Copyright © 2008 Elsevier Ltd. All rights reserved.